Latest Lead News

Bapcor Limited has reshaped its leadership with Lachlan Edwards appointed as Chair and Angus McKay stepping down from the Board to concentrate on turning around the business as CEO.

Jcurve Solutions has updated its revenue recognition policy for its ERP subscription licenses, shifting from point-in-time to over-time recognition, leading to restated FY25 financials and enhanced transparency.

DroneShield Limited reaffirms strong business fundamentals with record revenues in 2025, while addressing recent media reports and initiating an independent governance review.

Island Pharmaceuticals has secured membership in the Medical Countermeasures Coalition, positioning its antiviral Galidesivir for critical US government stockpiling and regulatory milestones.

Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, has landed three new cloud-based contracts worth a combined minimum of A$29 million, reinforcing its strong foothold across diverse healthcare segments.

Belararox Ltd announces the immediate resignation of founding Managing Director Arvind Misra, with Chairman Neil Warburton stepping in as interim leader during the search for a new executive director.

Icetana reveals its FY26 strategy focused on transforming Security Operations Centers with predictive, explainable, and autonomous AI, aiming to enhance threat detection and operational efficiency.

Echo IQ has completed a pivotal clinical validation of its EchoSolv HF software at the Mayo Clinic, achieving outstanding accuracy ahead of its FDA submission. This milestone sets the stage for potential US market entry into a $60 billion heart failure diagnostics sector.

Black Cat Syndicate announces a leadership transition with James Bruce appointed as Managing Director from April 2026, succeeding founder Gareth Solly who will remain as a Non-Executive Director.

Altech Batteries has secured a strategic collaboration with a leading global battery manufacturer to evaluate its breakthrough Silumina Anodes™ silicon-enhanced technology, marking a significant step toward commercialisation.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for PYC-003, an RNA therapy targeting Polycystic Kidney Disease. This milestone moves the drug closer to pivotal Phase 2/3 trials.

Ryman Healthcare has completed a full refinancing of its $2 billion syndicated loan facilities, extending the average maturity to five years and enhancing funding flexibility. The move aligns with the company’s disciplined growth strategy and sets the stage for future capital management decisions.